Cagrilintide

Cagrilintide is a long-acting amylin analog developed by Novo Nordisk, and the community runs it almost entirely for weight loss and appetite suppression, frequently combined with semaglutide. Clinician sources converge on a weekly dose around 2.4 mg, with some protocols reaching 4.5 mg over 26–32 week cycles; community modal dosing data remains thin. Injection-site reactions appear consistently across community reports — expect them as a routine feature of the protocol rather than a rare outlier.

Cagrilintide

Research Evidence

Evidence shape

The strongest evidence is a single Phase 3 trial in Type 2 diabetes — the only registered trial with posted results — showing a 0.3-point HbA1c reduction and a published adverse event profile. Forty trials span obesity, cardiovascular disease, chronic kidney disease, alcohol-related liver disease, and more, but 39 have no posted efficacy data. Obesity draws sixteen of those trials and none have posted outcomes, so the indication with the most clinical activity is the one with no public confirmation.

Depthhow much
41 registered trials
20 completed · 1 with posted results · 21 recruiting / active · combined n=92
Breadthhow many areas
12 indications mapped
1 with results · 10 thin / exploratory · 1 animal-only · 6 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
1 blinded with results · AE table from NCT04982575 · 6 linked publications on registered trials
Breadth and depth47 rows captured
Human
direct clinical signal
41
Animal
translational support
2
In vitro
mechanistic support
4
HighMediumLow

Anecdotal efficacy

Side effects

Clinical research side effects

Anecdotal side effects

Price

1
luxaralabs.com
--
2000 mg
$130.09
$0.065/mg
2
Nextgenpeps
US
10 mg
$1.32
$0.132/mg
3
luxaralabs.com
--
60 mg
$85.00
$1.42/mg
4
High Purity Peptides
HK
100 mg
$220.00
$2.2/mg
5
Nexaph
US
100 mg
$458.00
$4.58/mg
6
Peptira
US
10 mg
$49.00
$4.9/mg

price offers can be sorted by column

1-6 of 76

Dosing & Protocol

How Cagrilintide is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 20
Typical dose
No quantified dose captured for this tier.
Timing
unspecified
Cycle
unspecified

20 completed trials identified; trial dosing not reliably extracted from registry data.

8 sources
Clinician practice
Doctor & published-protocol guidance · n = 3
Starting dose
250 µg250 µg – 2.4 mg
250 µg
500 µg
1 mg
2 mg
Frequency
weekly
Timing
unspecified
Route
subQ
Cycle
unspecified

Clinician protocols dose 250 µg–2.4 mg weekly subQ (3 sources).

3 sources
Anecdotal
Community-reported real-world use · n = 43
Typical dose
No quantified dose captured for this tier.
Frequency
unspecified
Timing
unspecified
Route
not specified
Cycle
unspecified

Anecdotal reports primarily focus on weight loss and appetite control, with 67.4% of 43 reports showing positive outcomes for these uses. Specific dosing protocols were not consistently reported within community discussions.

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Peptide feedback

0 forum replies

Live community discussion for Cagrilintide, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.